Braun C, Azzano P, Gingras-Lessard F, Roy É, Samaan K, Graham F, Paradis L, Des Roches A, Bégin P. Front Med (Lausanne). 2023 Jun 28;10:1198173. doi: 10.3389/fmed.2023.1198173.
Abstract
Context: While oral immunotherapy (OIT) has been shown to promote the remission of mild peanut allergy in young children, there is still an unmet need for a disease-modifying intervention for older patients and those with severe diseases. In mice models, abatacept, a cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) immunoglobulin fusion protein, has been shown to promote immune tolerance to food when used as an adjuvant to allergen immunotherapy. The goal of this study is to explore the potential efficacy of abatacept in promoting immune tolerance to food allergens during OIT in humans.
| ATARI study design. |







